Abstract
Psoriatic arthritis (PsA) is an inflammatory arthritis which develops in up to one-third of patients suffering from the cutaneous disorder, psoriasis. The complex and heterogeneous nature of PsA renders it difficult to diagnose, leading to poor outcomes and, therefore, warrants an examination into soluble biomarkers, which may facilitate early detection of the disease. Protein biomarkers are a dynamic resource of pathophysiological information able to provide an immediate reflection of pathological changes caused by disease. Investigations of the serum and synovial fluid of PsA patients has provided new insights into the molecular basis of this disease and led to the identification of sensitive diagnostic and prognostic biomarkers. The collection of novel PsA biomarkers identified through proteomic studies has been reviewed below.
Highlights
Psoriasis is a chronic, immune-driven cutaneous disease afflicting nearly 2% of the global population
psoriatic arthritis (PsA) is an inflammatory arthritis that manifests in roughly 30% of psoriasis patients and in
PsA detection is guided by the criteria outlined in the Classification Criteria for Psoriatic Arthritis pre-symptomatic and early clinical stages to ensure prompt management of a potentially (CASPAR) [10]
Summary
Immune-driven cutaneous disease afflicting nearly 2% of the global population. PsA detection is guided by the criteria outlined in the Classification Criteria for Psoriatic Arthritis pre-symptomatic and early clinical stages to ensure prompt management of a potentially (CASPAR) [10] This first includes a judgment by a rheumatologist that the patient has an inflammatory debilitating disease. PsA detection is guided by the criteria outlined in the Classification musculoskeletal disease, followed by a review of the individual’s family and personal history of Criteria for Psoriatic Arthritis (CASPAR) [10] This first includes a judgment by a rheumatologist psoriasis, past or present of dactylitis, nail psoriasis, the absence of serum rheumatoid that the patient has evidence an inflammatory musculoskeletal disease, followed by a review of thefactor and radiographic evidence of new bone formation [2]. The dynamic state of protein levels and their respective PTMs aids in the ability to delineate key pathways involved in the onset of arthritic disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
